Cipla faces revenue and margin pressure ahead of Revlimid patent expiry

Cipla has lagged behind sector indices over the past year, as anticipated pressure on revenue and margins looms due to the upcoming expiry of the Revlimid patent next year. The company projects a year-on-year margin decline of 140–240 basis points in the current fiscal.